Details for Patent: 7,094,781
✉ Email this page to a colleague
Which drugs does patent 7,094,781 protect, and when does it expire?
Patent 7,094,781 protects OPSUMIT and OPSYNVI and is included in two NDAs.
Protection for OPSUMIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-one patent family members in twenty-three countries.
Summary for Patent: 7,094,781
| Title: | Sulfamides and their use as endothelin receptor antagonists |
| Abstract: | The invention relates to novel sulfamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists. |
| Inventor(s): | Martin Bolli, Christoph Boss, Walter Fischli, Martine Clozel, Thomas Weller |
| Assignee: | Actelion Pharmaceuticals Ltd |
| Application Number: | US10/433,041 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,094,781 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 7,094,781
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actelion | OPSUMIT | macitentan | TABLET;ORAL | 204410-001 | Oct 18, 2013 | AB | RX | Yes | Yes | 7,094,781*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Actelion | OPSYNVI | macitentan; tadalafil | TABLET;ORAL | 218490-001 | Mar 22, 2024 | RX | Yes | No | 7,094,781*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Actelion | OPSYNVI | macitentan; tadalafil | TABLET;ORAL | 218490-002 | Mar 22, 2024 | RX | Yes | Yes | 7,094,781*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,094,781
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| PCT/EP00/12890 | Dec 18, 2000 | |
| PCT Information | |||
| PCT Filed | December 04, 2001 | PCT Application Number: | PCT/EP01/14182 |
| PCT Publication Date: | July 11, 2002 | PCT Publication Number: | WO02/053557 |
International Family Members for US Patent 7,094,781
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1345920 | ⤷ Start Trial | CA 2014 00012 | Denmark | ⤷ Start Trial |
| European Patent Office | 1345920 | ⤷ Start Trial | 92381 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 1345920 | ⤷ Start Trial | C300672 | Netherlands | ⤷ Start Trial |
| European Patent Office | 1345920 | ⤷ Start Trial | 14C0017 | France | ⤷ Start Trial |
| European Patent Office | 1345920 | ⤷ Start Trial | 1490025-2 | Sweden | ⤷ Start Trial |
| European Patent Office | 1345920 | ⤷ Start Trial | C01345920/01 | Switzerland | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
